

# The Medical Letter®

## On Drugs and Therapeutics

---

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

---

**IN THIS ISSUE** (starts on next page)

---

**In Brief: Lowering the Dose of *Lunesta*** ..... p 48

### Important Copyright Message

The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

**For further information click: [Subscriptions, Site Licenses, Reprints](#)  
or call customer service at: 800-211-2769**

---

**FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS**

# The Medical Letter®

## On Drugs and Therapeutics

---

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

---

Volume 56 (Issue 1444)  
June 9, 2014

[www.medicalletter.org](http://www.medicalletter.org)  
[Take CME Exams](#)

### IN BRIEF

---

#### Lowering the Dose of *Lunesta*

The FDA has required the manufacturer of eszopiclone (*Lunesta* – Sunovion), a benzodiazepine receptor agonist approved for the treatment of insomnia, to lower the current recommended starting dose to 1 mg for both men and women because a new study found that an evening dose of 3 mg can impair driving skills, memory, and coordination for more than 11 hours.<sup>1</sup> Eszopiclone's half-life is longer than that of any other drug in its class, which includes zolpidem (*Ambien*, and generics) and zaleplon (*Sonata*, and generics).

All benzodiazepine receptor agonists may impair performance the next morning, including driving.<sup>2</sup> Anterograde amnesia and complex sleep-related behaviors without conscious awareness may also occur. Hallucinations have been reported. Like the benzodiazepines, benzodiazepine receptor agonists are schedule IV controlled substances; withdrawal, dependence, and abuse can occur.

1. FDA Drug Safety Communication. FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose. Available at [www.fda.gov/Drugs/DrugSafety/ucm397260.htm](http://www.fda.gov/Drugs/DrugSafety/ucm397260.htm). Accessed May 29, 2014.
2. Drugs for insomnia. *Treat Guidel Med Lett* 2012; 10:57.

The Medical Letter®  
On Drugs and Therapeutics

**EDITOR IN CHIEF:** Mark Abramowicz, M.D.

**EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School

**EDITOR:** Jean-Marie Pflomm, Pharm.D.

**ASSISTANT EDITORS, DRUG INFORMATION:** Susan M. Daron, Pharm.D.,  
Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D.

**CONSULTING EDITORS:** Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:**

Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons

Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School

Eric J. Epstein, M.D., Albert Einstein College of Medicine

Jane P. Gagliardi, M.D., M.H.S., F.A.C.P. Duke University School of Medicine

Jules Hirsch, M.D., Rockefeller University

David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre

Richard B. Kim, M.D., University of Western Ontario

Hans Meinertz, M.D., University Hospital, Copenhagen

Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine

Dan M. Roden, M.D., Vanderbilt University School of Medicine

Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School

F. Estelle R. Simons, M.D., University of Manitoba

Neal H. Steigbigel, M.D., New York University School of Medicine

Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**SENIOR ASSOCIATE EDITOR:** Amy Faucard

**MANAGING EDITOR:** Susie Wong

**ASSISTANT MANAGING EDITOR:** Liz Donohue

**PRODUCTION COORDINATOR:** Cheryl Brown

**EXECUTIVE DIRECTOR OF SALES:** Gene Carbona

**FULFILLMENT & SYSTEMS MANAGER:** Cristine Romatowski

**DIRECTOR OF MARKETING COMMUNICATIONS:** Joanne F. Valentino

**VICE PRESIDENT AND PUBLISHER:** Yosef Wissner-Levy

Founded in 1959 by  
Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter is an independent nonprofit organization that provides health care professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants, or donations. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

**Subscription Services**

**Mailing Address:**

The Medical Letter, Inc.  
145 Huguenot St. Ste. 312  
New Rochelle, NY 10801-7537

**Customer Service:**

Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
Web Site: [www.medicalletter.org](http://www.medicalletter.org)  
E-mail: [custserv@medicalletter.org](mailto:custserv@medicalletter.org)

**Permissions:**

To reproduce any portion of this issue,  
please e-mail your request to:  
[permissions@medicalletter.org](mailto:permissions@medicalletter.org)

**Subscriptions (US):**

1 year - \$98; 2 years - \$189;  
3 years - \$279. \$49.00 per year for  
students, interns, residents, and  
fellows in the US and Canada.

**E-mail site license inquiries to:**

[info@medicalletter.org](mailto:info@medicalletter.org) or call  
800-211-2769 x315.  
Special fees for bulk subscriptions.  
Special classroom rates are available.  
Back issues are \$12 each. Major credit  
cards accepted.

Copyright 2014. ISSN 1523-2859